| Project/Area Number |
23580443
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Clinical veterinary science
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KINOSHITA Asuka (SETOGUCHI Asuka) 鹿児島大学, 共同獣医学部, 准教授 (00396813)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Keywords | 犬 / 癌 / 腫瘍 / ワクチン / 癌ワクチン / アジュバント / リンパ腫 |
|---|
| Research Abstract |
TThe aim of this study is to establish new tumor vaccine for canine naturally occurring tumor. We synthesized peptides in reference to epitope of tumor specific antigens. The peptides were conjugated with keyhole limpet hemocyanin and absorbed to the surface of nano-particle (adjuvant). The resultant products successfully induced antibody production against the peptide, however, cellular immunity against the target cells was not detected. Adverse events were not observed in vaccinated dogs but the clinical benefit (objective tumor reduction) was not detected in a dog with lymphoma. We newly reported canine TRP-2 cDNA nucleotide sequence and constructed TRP-2, melan-A, CD20-GFP fusion molecule, mammalian expression plasmid. The findings obtained in this study may be helpful to establish canine tumor vaccine.
|
